GMAS has published a large number of primary research papers and commentaries.
Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Orphanet Journal of Rare Diseases 2011, 6:62.
Related Scrip article: Orphan drugs won't bankrupt EU healthcare budgets, 28 October 2011
Olivia EN, Schey C, Hutchings A. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. Am J Blood Res 2011;1(2):160-166. (Link)
Connolly MP, Topachevskyi O, Standaert B, Ortega O, Postma M. The impact of rotavirus vaccination on discounted net tax revenue in Egypt: A government perspective analysis. PharmacoEconomics in press.
Connolly MP. Cross-border reproductive care: market forces in action or market failure? An economic perspective. Reproductive BioMedicine Online. Accepted for publication. DOI information: 10.1016/j.rbmo.2011.09.006.
Connolly MP, Simoens S. Kiovig for primary immunodeficiency: Reduced infusion and cost per infusion. Int Immunopharmacol 2011 May 12. [Epub ahead of print]
Hutchings A, Calloway M, Choy E, Hooper M, Hunter DJ, Jordan JM, Zhang Y, Baser O, Long S, Palmer L. The Longitudinal Examination of Arthritis Pain (LEAP) study: relationships between weekly fluctuations in patient-rated joint pain and other health outcomes. J Rheumatol 2007 Nov;34(11):2291-300
And related Editorial:
Allen K. The value of measuring variability in osteoarthritis pain. J Rheumatology 2007;34(11):2132-2133
Connolly MP, Hoorens S, Chambers GM; ESHRE Reproduction and Society Task Force. The costs and consequences of assisted reproductive technology: an economic perspective. Hum Reprod Update 2010;16(6):603-13. (Link)
Related Newsweek article (Link)
Connolly MP. The Economics of Assisted Reproduction: Costs and consequences of fertility treatments. Thesis from University of Groningen library 2010. (Link)
Connolly MP, Postma MJ. Healthcare as an investment: Implications for an era of ageing populations. J Med Mark 2010;10(1):5-14. (PDF).
Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. Journal of Crohn’s and Colitis 2010;4(3):275-282.
Hutchings A. Rewarding innovation? An assessment of the factors that affect price and reimbursement status in Europe. J Med Mark 2010;10(1):83-90. (PDF).
Connolly MP, Constenla D. Assessing economic benefits for government and society attributed to malaria investment strategies: An exploratory analysis based on malaria vaccination. The Multilateral Initiative on Malaria (MIM), Nairobi, 2-6 November 2009. Poster 856. (PDF).
Connolly MP, Postma M, Silber S. What's on the mind of IVF consumers? Reprod Biomed Online 2009;19(6):767-9.
Connolly MP. The potential economic benefit of maintaining a healthy workforce should be considered when valuing health technologies. Pharmaceutical Marketing – Feature Article; September 2009.
Connolly MP, et al. Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis. Digestion 2009;80(4):241-6.
Connolly MP, Ledger W, Griesinger G, Postma M. The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: A price-elasticity of demand assessment. Hum Reprod 2009;24(11):2796-800.
Connolly M, Bhatt A. Implementation of National Dyspepsia Guidelines to Reduce Prescribing and Return Patients to Self Care: Results from An Educational Intervention and Prospective Clinical Audit in England. Gastroenterology 2009;136(5 suppl):A-72.
Wex J, Connolly M, Rath W. Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation. BMC Pregnancy and Childbirth 2009;9:23.
Connolly M, Bhatt A. Implementation of national dyspepsia guidelines to reduce prescribing and return patients to self care: results from an educational intervention and prospective clinical audit in England. Pharmacoepidemiology and drug safety 2009;18:1–11.
Connolly M, et al. Assessing long-run economic benefits attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. Human Reprod 2009; 24(3):626-32.
Connolly M, et al. An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis. J Crohns Colitis 2009;3:168-74.
Svensson A, Connolly M, Gallo F, Hägglund L. Long-term fiscal implications of subsidizing in-vitro fertilization in Sweden: a lifetime tax perspective. Scand J Public Health 2008;36:841-9.
Connolly M, Bhatt A. A comparison of treatment failure rates based on starting alginate therapy observed in a large representative longitudinal UK database. Value Health 2008;11(6):A530.
Connolly MP, et al. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. J Crohns Colitis 2009;3:32-7.
Maniadakis N., N. Kotsopoulos, P. Prezerakos, and J. Yfantopoulos. Measuring Intra-Hospital Clinic Efficiency and Productivity: An Application to a Greek University General Hospital. Eur Res Stud J 2008; XI(1-2):95-110.
Connolly M. Pricing and reimbursement challenges for new pharmaceuticals and medical devices. www.lifescience-online.com (Oct 2008).
Connolly MP, Ledger W. Price-elasticity of demand for infertility services in Germany. Value Health 2008:11(6).
Bhatt A, Connolly M, Travis SPL. Self-diagnosis and health seeking behaviour of women for minor bowel ailments in a large representative United Kingdom (UK) sample population. Gut 2008;57(Suppl I):A271. (PDF)
Connolly M, et al. Once daily mesalazine for maintaining remission is cost-saving compared to twice daily mesalazine: An economic evaluation based on the PODIUM randomised controlled trial. Gut 2008;57 (Suppl I):A261.
Connolly M, et al. Long-term economic benefits attributed to IVF conceived children: A lifetime tax calculation. Am J ManagCare 2008; 14(9):598-604.
Connolly M, De Vrieze K, Ombelet W, Schneider D, Currie CJ. A cost per live birth comparison based on a systematic review of hMG and rFSH randomised trials. Reprod BioMed Online 2008;17(6):756-63.
Wex J, Connolly M, Schneider D, Rath W, Nielsen SK. Atosiban is cost saving when compared to beta-mimetics in the treatment of preterm labour in Germany. European Congress of Perinatal Medicine, September 2008.
Connolly M, Bhatt A, Wechowski J, Colli I. An economic evaluation of vasoactive agents used to treat acute bleeding oesophageal varices in Belgium. Acta Gastroenterol Belg 2008;71:230-36.
Nielsen S, Connolly M, Persson BE. Variation between countries in the perceived use of antiandrogens to prevent flare symptoms: results of a comprehensive survey. EAU Milan 2008.
Moul JW, Wiederkehr D, Connolly M, Sendersky V, Onel E. The relationship between LHRH-agonist depot formulations and frequency of follow-up with health care providers in patients with prostate cancer. J Clin Oncol 2008;26(Suppl): abstract 16002.
Moul JW, Wiederkehr D, Sendersky V, Connolly M, Stern L, Onel E. The influence of Medicare reform on the utilization of anti-androgens in a cohort of patients with prostate cancer in the United States. Am Soc Clin Oncol 2008; abstract 204.
Wechowski J, Connolly M, Schneider D, McEwan P, Kennedy R. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha. Fertil Steril 2009;91(4):1067-76.
Svensson A, Connolly M, Gallo F, Hägglund L. Long-term fiscal implications of subsidizing in-vitro fertilization in Sweden: a lifetime tax perspective. Scand J Public Health 2008;36(8):841-9.
Connolly MP, Hoorens S, Gallo F, Ledger W. Assessment of long term economic benefits associated with in-vitro fertilization funding decisions: A simplified lifetime tax calculation. Value Health 2007;10(6):ES7.
Maniadakis N, Kotsopoulos N, Prezerakos P, and Yfantopoulos J. Health Care Services Performance Measurement: Theory, Methods and Empirical Evidence. Eur Res Stud J 2007;X(1-2).
Prezerakos P, Maniadakis N, Kaitelidou D, Kotsopoulos N, Yfantopoulos J. Measuring Across Hospital Efficiency and Productivity: The Case of Second Regional Health Authority of Attica. Eur Res Stud J 2007;X(1-2).
Nielsen SK, Currie CJ, Connolly MP, Bhatt A. Evaluation of improvement in health-related quality of life using oral mesalazine alone or in combination with mesalazine enema in active ulcerative colitis: Results from a randomised controlled trial. Value Health 2007;10(6):PR8.
Connolly MP, Nielsen SK, Bhatt A, Currie CJ, Probert CS, Marteau P. Evaluation of the cost-effectiveness of concomitant oral and topical versus oral mesalazine therapy in mild-to-moderate active ulcerative colitis: A decision-analytic model. Gut 2007;56:(Suppl III):A149.
Connolly MP, S. Hoorens, and W. Ledger Money in babies out: Assessing the long-term economic impact of IVF conceived children. J Medical Ethics 2008;34:653-4.
Wechowski J, McEwan P, Connolly MP,Kennedy R. HP-hMG (Menopur®) is cost-saving in IVF compared to rFSH (Gonal-F®) in an economic evaluation using two large combined randomised controlled trials. Human Reprod 2007;22(7):0-52.
Connolly MP, Currie CJ, Nielsen SK. Cost-saving treatment strategies in cervical ripening/labour induction: A cost comparison of two dinoprostone formulations. J Perinat Med 2007;35:(S139).
Wechowski J, Connolly M, McEwan P, Kennedy R. An economic evaluation of HP-hMG and rFSH based on a large randomised trial. Reprod BioMedicine Online 2007;15:500-06.
M Connolly. Demography is destiny: the long term societal impact of assisted reproduction. Portuguese Infertility Society Annual Meeting (Porto), May 19th 2007 (Invited speaker).
Wechowski J, Connolly M, Tetlow A, McEwan P, et al. An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis. Curr Med Res Opin 2007; 23(7):1481-91.
Wechowski J, McEwan P, Connolly M, Kennedy R. Costs and effectiveness of highly purified human menopausal gonadotropin (HP-hMG) versus recombinant follitropin alpha (rFSH) in IVF treatment: A United Kingdom discrete event simulation model. 19th World Congress on Infertility and Sterility 2007; Durban (oral presentation).
Hoorens S, Gallo F, Ledger W, Connolly M. The impact of NHS funding decisions for in vitro fertilisation (IVF) on Treasury department revenues: A simplified lifetime net tax calculation. National Institute for Clinical Excellence (NICE) annual meeting, Dec 2006.
McCrink L, Allen RP, Wolowacz S, Sherrill B, Connolly M, Kirsch J. Predictors of health-related quality of life in sufferers with restless legs syndrome: A multi-national study. Sleep Medicine (2006);8(1):73-83.
Wechowski J, Tetlow T, Woehl Al, Connolly M, Currie CJ, Burroughs AK. An economic evaluation of terlipressin versus alternative vasoactive drug treatments for acute oesophageal variceal bleeding in cirrhotic patients: A UK decision-analytic model. 14th United European Gastroenterology Week; 2006: Berlin (256).
Ledger W, Gallo F, Hoorens S, Ziebe S, Connolly M. Present discounted value of children born using IVF compared with naturally conceived children: A simplified UK tax calculation. Hum Rep vol. 21(Suppl 1); 2006 (i74).
Wechowski J, Tetlow T, Woehl A, Currie CJ, Connolly M, Bhatt A, Colle I. Economic evaluation of vasoactive management options for acute oesophageal variceal bleeding in cirrhotic patients: A Belgian comparison. Ceska a Slovenska Gastrologie a Hepatologie 2006;60,S1:119.
Connolly M. Impact of introducing reference-based pricing on prescription drug claims in Australia. 5th European Conference on Health Economics, abstract 63, London, Sept 2004. (PDF)
Lees M, Isaacson, W, Fulcer G, Yue M, Connolly M, Currie CJ. Cost-effectiveness of intensive insulin therapy using insulin glargine versus NPH insulin in an Australian population. International Diabetes Federation Sept. 2003 (Abstract 2922).
Lovibond K, Hutchings A, O'Leary M. An Exploration of Incremental Net Health Benefit Analysis: A Quantitative Assessment of the Benefit-Harm Profile of Natalizumab in Relapsing Remitting Multiple Sclerosis. iHEA Explorations in Health Economics Paper 2006.
Ozdemir, S., F.R. Johnson, T. Kauf, M.O. Calloway, and A. Hutchings. Can osteoarthritis patients evaluate tradeoffs between NSAID risks and benefits? Value in Health 2006;9(3):29
